新石阳光药业

Beijing Xinshi Sunshine Pharmaceutical is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the discovery and development of innovative small molecule drugs. Founded in 2010, the company focuses on therapeutic areas with significant unmet medical needs, primarily oncology. Its lead candidate, XS-02, is a novel small molecule protein kinase inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors. The company maintains a strong focus on internal R&D and intellectual property, aiming to advance Class 1 innovative medicines within the Chinese regulatory framework.